GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

A new study supports the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move could jeopardize the availability of cheaper, generic forms of those drugs ...

Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

In response to the FDA’s shortage decision, Hims & Hers is launching a new GLP-1 tracker, allowing patients to self-identify, provide ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...